1. Home
  2. RYTM vs KNX Comparison

RYTM vs KNX Comparison

Compare RYTM & KNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RYTM
  • KNX
  • Stock Information
  • Founded
  • RYTM 2008
  • KNX 1989
  • Country
  • RYTM United States
  • KNX United States
  • Employees
  • RYTM N/A
  • KNX N/A
  • Industry
  • RYTM Biotechnology: Pharmaceutical Preparations
  • KNX Trucking Freight/Courier Services
  • Sector
  • RYTM Health Care
  • KNX Industrials
  • Exchange
  • RYTM Nasdaq
  • KNX Nasdaq
  • Market Cap
  • RYTM 6.4B
  • KNX 7.4B
  • IPO Year
  • RYTM 2017
  • KNX 1994
  • Fundamental
  • Price
  • RYTM $98.54
  • KNX $44.87
  • Analyst Decision
  • RYTM Strong Buy
  • KNX Strong Buy
  • Analyst Count
  • RYTM 12
  • KNX 17
  • Target Price
  • RYTM $117.00
  • KNX $53.65
  • AVG Volume (30 Days)
  • RYTM 629.6K
  • KNX 4.2M
  • Earning Date
  • RYTM 11-04-2025
  • KNX 10-22-2025
  • Dividend Yield
  • RYTM N/A
  • KNX 1.61%
  • EPS Growth
  • RYTM N/A
  • KNX 280.63
  • EPS
  • RYTM N/A
  • KNX 0.88
  • Revenue
  • RYTM $174,334,000.00
  • KNX $7,477,640,000.00
  • Revenue This Year
  • RYTM $46.10
  • KNX $2.37
  • Revenue Next Year
  • RYTM $63.02
  • KNX $5.58
  • P/E Ratio
  • RYTM N/A
  • KNX $51.06
  • Revenue Growth
  • RYTM 54.92
  • KNX N/A
  • 52 Week Low
  • RYTM $45.91
  • KNX $36.69
  • 52 Week High
  • RYTM $116.00
  • KNX $61.51
  • Technical
  • Relative Strength Index (RSI)
  • RYTM 39.87
  • KNX 51.39
  • Support Level
  • RYTM $95.27
  • KNX $43.78
  • Resistance Level
  • RYTM $102.20
  • KNX $46.56
  • Average True Range (ATR)
  • RYTM 4.86
  • KNX 1.70
  • MACD
  • RYTM -1.75
  • KNX -0.11
  • Stochastic Oscillator
  • RYTM 17.51
  • KNX 48.81

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.

About KNX Knight-Swift Transportation Holdings Inc.

Knight-Swift is the largest full-truckload carrier in the US, with a diversified transportation offering. Pro forma for the US Xpress deal, about 82% of revenue derives from Knight's asset-based trucking business, with full truckload (for-hire dry van, refrigerated, and dedicated contract) making up 69% and less than truckload 13%. Truck brokerage and other asset-light logistics services make up 9% of revenue, with intermodal near 6%. Knight's intermodal operations use the Class I railroads for the underlying movement of its shipping containers and include drayage (regional trucking services to and from inland intermodal ramps/terminals). The remainder of revenue reflects services offered to shippers and third-party truckers, including equipment maintenance and leasing.

Share on Social Networks: